©The Author(s) 2025.
World J Cardiol. Nov 26, 2025; 17(11): 109287
Published online Nov 26, 2025. doi: 10.4330/wjc.v17.i11.109287
Published online Nov 26, 2025. doi: 10.4330/wjc.v17.i11.109287
Table 4 Comparison of serum inflammatory levels before and after treatment in the two groups of patients, mean ± SD
| Group | IL-6 (μg/L) | CRP (pg/mL) | TNF-α (ng/L) | MMP-9 (ng/L) | |
| Observation group | PCI postoperative | 8.4 ± 1.7 | 78.9 ± 17.0 | 129.2 ± 20.1 | 16.9 ± 1.1 |
| Review after 1 month | 6.0 ± 1.0 | 41.7 ± 6.4 | 112.9 ± 14.0 | 14.9 ± 1.1 | |
| t (P value) | 11.2 (0.21) | 19.2 (0.01a) | 9.4 (0.07) | 17.0 (0.08) | |
| Control group | PCI postoperative | 8.4 ± 1.4 | 76.1 ± 18.9 | 124.1 ± 14.7 | 16.3 ± 1.8 |
| Review after 1 month | 4.7 ± 2.4 | 23.0 ± 7.9 | 83.7 ± 10.8 | 12.3 ± 0.7 | |
| t (P value) | 22.0 (0.01a) | 24.3 (< 0.01a) | 24.0 (0.01a) | 20.2 (0.12) | |
- Citation: Li J, Li XR, Kong MW, Zhang J. Medium-to-long term outcomes of bioresorbable scaffold treatment in patients with acute coronary syndrome. World J Cardiol 2025; 17(11): 109287
- URL: https://www.wjgnet.com/1949-8462/full/v17/i11/109287.htm
- DOI: https://dx.doi.org/10.4330/wjc.v17.i11.109287